Carolina Figueiredo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Carolina Figueiredo has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- André Pinho
Dermatology and Venereology Department Unidade Local de Saúde de Coimbra Coimbra Portugal
3 shared publications - Margarida Gonçalo
Department of Dermatology University Hospital, Unidade Local de Saude de Coimbra Coimbra Portugal
3 shared publications - Ana Brinca
Department of Dermatology, Coimbra University Hospital, Coimbra, Portugal
2 shared publications - David Gaspar Caetano
Dermatology Department, Local Health Unit of Coimbra, Portugal
2 shared publications - Duarte Flor
Dermatology Department, Coimbra Hospital and University Centre, Coimbra, Portugal
2 shared publications - Mariana Pedroso
Dermatology Department Coimbra University Hospital Coimbra Portugal
2 shared publications
Latest Publications
- 7 October 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Systemic Lupus Erythematosus
- 7 October 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Systemic Lupus Erythematosus
- 6 September 2026
- Published by Wiley in Contact Dermatitis
- Vol. 95 (6) , 609-610
Recurrent Facial Pustules With ‘In Situ’ Patch Test Positivity
- 6 September 2026
- Published by Wiley in Contact Dermatitis
- Vol. 95 (6) , 609-610
Recurrent Facial Pustules With ‘In Situ’ Patch Test Positivity
- Open Access
- 3 April 2026
- Published by Wiley in Contact Dermatitis
- Vol. 95 (1) , 65-73
Skin Sensitisation and Dermatitis Among Epoxy‐Exposed Workers in a Wind Turbine Plant: Influence of Occupational Factors
Background: Epoxy polymers, widely used in industries such as wind turbine production, are common causes of allergic contact dermatitis (ACD). However, gaps remain mostly regarding the type of occupational exposure (specific tasks) and protective strategies. Objectives: To evaluate epoxy resin sensitisation in a wind turbine blade plant and assess its associations with tasks, medical history, clinical patterns, and personal protective equipment (PPE) use. Methods: A cross‐sectional study was performed in a large wind turbine blade facility. A group of volunteer workers completed a questionnaire on occupational/medical history, PPE use, and symptoms. Onsite patch testing included the European Baseline‐, epoxy‐, and isocyanate series. Data were analysed using SPSS and R ( p < 0.05). Results: Among 131 workers tested (7.4% of the workforce), seven (5.3%), all from high‐exposure tasks, showed positive reactions to epoxy compounds: Bisphenol F resin (5), Bisphenol A resin (4), and hardeners/additives (5). Hand dermatitis was the predominant ACD pattern, with a median time to onset of 8 months after employment. No associations were found between sensitisation and previous medical history or PPE compliance. Conclusions: The ACD to epoxy resin is a significant concern in wind turbine blade manufacturing. Accurate diagnosis requires patch testing with epoxy‐specific series, beyond the European Baseline series. Prevention should extend beyond PPE, addressing airborne exposure and cross‐contamination.
- 3 April 2026
- Published by Wiley in Contact Dermatitis
- Vol. 95 (1) , 65-73
Open AccessSkin Sensitisation and Dermatitis Among Epoxy‐Exposed Workers in a Wind Turbine Plant: Influence of Occupational Factors
Background: Epoxy polymers, widely used in industries such as wind turbine production, are common causes of allergic contact dermatitis (ACD). However, gaps remain mostly regarding the type of occupational exposure (specific tasks) and protective strategies. Objectives: To evaluate epoxy resin sensitisation in a wind turbine blade plant and assess its associations with tasks, medical history, clinical patterns, and personal protective equipment (PPE) use. Methods: A cross‐sectional study was performed in a large wind turbine blade facility. A group of volunteer workers completed a questionnaire on occupational/medical history, PPE use, and symptoms. Onsite patch testing included the European Baseline‐, epoxy‐, and isocyanate series. Data were analysed using SPSS and R ( p < 0.05). Results: Among 131 workers tested (7.4% of the workforce), seven (5.3%), all from high‐exposure tasks, showed positive reactions to epoxy compounds: Bisphenol F resin (5), Bisphenol A resin (4), and hardeners/additives (5). Hand dermatitis was the predominant ACD pattern, with a median time to onset of 8 months after employment. No associations were found between sensitisation and previous medical history or PPE compliance. Conclusions: The ACD to epoxy resin is a significant concern in wind turbine blade manufacturing. Accurate diagnosis requires patch testing with epoxy‐specific series, beyond the European Baseline series. Prevention should extend beyond PPE, addressing airborne exposure and cross‐contamination.
- Open Access
- 18 September 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (4) , 693-694
Plexiform neurofibroma
- 18 September 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (4) , 693-694
Open AccessPlexiform neurofibroma
- Open Access
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
EASI 100 as a Therapeutic Target in Pediatric Atopic Dermatitis
Dupilumab, a monoclonal antibody targeting interleukin‐4 receptor alpha, has shown both robust efficacy and safety in pediatric atopic dermatitis (AD), but data on complete disease control (Eczema Area and Severity Index [EASI] 100) are scarce. A retrospective analysis of 25 pediatric patients at our institution with a median treatment duration of 20 months revealed a significant improvement in EASI scores, with 44.0% achieving EASI 100 at a median of 52 weeks of treatment. No significant differences were found between the group of patients achieving EASI 100 and those who did not. While this study provides additional insight into the efficacy and safety of dupilumab in pediatric AD, its limited sample size underscores the need for larger scale studies focusing on EASI 100 to better understand the factors influencing complete disease control and to optimize treatment strategies for pediatric patients with AD.
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Open AccessEASI 100 as a Therapeutic Target in Pediatric Atopic Dermatitis
Dupilumab, a monoclonal antibody targeting interleukin‐4 receptor alpha, has shown both robust efficacy and safety in pediatric atopic dermatitis (AD), but data on complete disease control (Eczema Area and Severity Index [EASI] 100) are scarce. A retrospective analysis of 25 pediatric patients at our institution with a median treatment duration of 20 months revealed a significant improvement in EASI scores, with 44.0% achieving EASI 100 at a median of 52 weeks of treatment. No significant differences were found between the group of patients achieving EASI 100 and those who did not. While this study provides additional insight into the efficacy and safety of dupilumab in pediatric AD, its limited sample size underscores the need for larger scale studies focusing on EASI 100 to better understand the factors influencing complete disease control and to optimize treatment strategies for pediatric patients with AD.
- Open Access
- 1 July 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (4) , 591-593
Predição de falha de enxertos de pele no couro cabeludo por análise intraoperatória com laser speckle
- 1 July 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 99 (4) , 591-593
Open AccessPredição de falha de enxertos de pele no couro cabeludo por análise intraoperatória com laser speckle
- Open Access
- 12 April 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (4) , 591-593
Predicting skin graft failure on the scalp by intraoperative laser speckle analysis
- 12 April 2024
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 99 (4) , 591-593
Open AccessPredicting skin graft failure on the scalp by intraoperative laser speckle analysis
- Open Access
- 15 March 2024
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 30 (1)
Three cases of Anti-MDA5 positive dermatomyositis with interstitial lung disease and pneumomediastium
Author(s): Figueiredo, Carolina; Matos, Ana Luisa; Calvao, Joana; Goncalo, Margarida
- 15 March 2024
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 30 (1)
Open AccessThree cases of Anti-MDA5 positive dermatomyositis with interstitial lung disease and pneumomediastium
Author(s): Figueiredo, Carolina; Matos, Ana Luisa; Calvao, Joana; Goncalo, Margarida
- 30 January 2024
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 28 (2) , 212
Pruritic Linear Rash Caused by Mushroom Ingestion
- 30 January 2024
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 28 (2) , 212
Pruritic Linear Rash Caused by Mushroom Ingestion
- Open Access
- 13 September 2023
- Published by PAGEPress Publications in Dermatology Reports
- Vol. 16 (3) , 9837
Discoid lupus erythematosus associated with chronic granulomatous disease
To the Editor, Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder in which a reduced activity of nicotinamide dinucleotide phosphate (NAPDH) oxidase leads to defective reactive oxygen intermediates (ROS) and impairs intracellular killing of microorganisms. Patients have recurrent bacterial and fungal infections as well as granuloma formations, and have a higher risk of autoimmune and inflammatory disorders like lupus erythematosus.1 A 20-year-old caucasian male with a diagnosis of autosomal recessive CGD was referred to our hospital because of a pruritic photosensitive rash on the face and hands, present for more than a year.
- 13 September 2023
- Published by PAGEPress Publications in Dermatology Reports
- Vol. 16 (3) , 9837
Open AccessDiscoid lupus erythematosus associated with chronic granulomatous disease
To the Editor, Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder in which a reduced activity of nicotinamide dinucleotide phosphate (NAPDH) oxidase leads to defective reactive oxygen intermediates (ROS) and impairs intracellular killing of microorganisms. Patients have recurrent bacterial and fungal infections as well as granuloma formations, and have a higher risk of autoimmune and inflammatory disorders like lupus erythematosus.1 A 20-year-old caucasian male with a diagnosis of autosomal recessive CGD was referred to our hospital because of a pruritic photosensitive rash on the face and hands, present for more than a year.